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  ABOUT THE JOURNAL   
 
 
Aims and Scope 
 
Psychiatry has suffered tremendously by the limited 
translational pipeline. Nobel laureate Julius Axelrod’s 
discovery in 1957 of monoamine reuptake by pre-synaptic 
neurons still forms the basis of contemporary antidepressant 
treatment. There is a substantial gap between the explosion of 
knowledge in neuroscience and conceptually novel treatments 
for our patients. 
 
Translational Psychiatry bridges this gap by fostering and 
highlighting the pathway from discovery to clinical 
applications, healthcare and global health. We view 
translation broadly, as the full spectrum of work that marks 
the pathway from discovery to global health. The steps of 
translation that are within the scope of Translational Psychiatry 
include 
(i) fundamental discovery, 
(ii) bench to bedside, 
(iii) bedside to clinical applications (clinical trials), (iv) 
translation to policy and health care guidelines, (v) 
assessment of health policy and usage, and 
(vi) global health. 
 
All areas of medical research, including – but not restricted to 
– molecular biology, genetics, pharmacology, imaging 
and epidemiology are welcome as they contribute to 
enhance the field of translational psychiatry. Translational 
Psychiatry invites submissions of original articles and 
reviews, along with invited editorials and perspectives, all 
of which fall within the field of translational psychiatry. 
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Deputy Director, Translational Medicine and Head, Mind 
and Brain Theme 
South Australian Health and Medical Research Institute 
 
Strategic Professor of Psychiatry 
Flinders University in Adelaide, South Australia 
 
Editorial office: 
Nature Publishing Group, 75 Varick St, 9th Floor, New York 
NY 10013 
TranslationalPsychiatry@nature.com 
 
Impact factor: 5.538 (2015 Journal Citation Reports, Thomson 
Reuters) 
Abstracted in: 
PubMed/MEDLINE 
PubMed Central 
Scopus 
ISI Web of Science 
DOAJ 
British Library 
Crossref
Revised January 20, 2015 2 
 
  ARTICLE TYPE SPECIFICATIONS   
 
 
 
Article Description 
Abstract  
 
Word Limit 
Tables/ 
Figures 
 
References 
 
 
 
Original Articles 
 
Please see ‘Preparation of Articles’ below for details. 
 
Unstructured 
abstract 
 
Abstract: 250 words 
 
Article: 5,000 words 
excluding abstract 
and references. 
 
 
Max of 5 Max of 100 
 
 
 
 
 
Reviews 
 
Unstructured 
abstract 
 
Abstract: 250 words 
 
Article: 6,000 words 
 
Max of 6-8 Max of 150 
 
Correspondence 
 
Correspondence contributions must respond to an original 
research article published in Translational Psychiatry no earlier 
than six months prior to the proposed letter’s submission. 
Original authors will have the opportunity to respond to the 
letter, should it be chosen for acceptance. This response will 
be published alongside the correspondence.  
 
Correspondence should contain no original or novel data. 
Contributions should start with a two- or three-sentence 
paragraph that contains the message of the article without 
specialized terminology. 
 
Joint first authors are not allowed. 
 
In consultation with the author, the editor may change the 
title of a Correspondence.
 
 
 
 
 
No abstract 
required 
 
 
 
 
 
 
 
Article: 700 words 
(900 if no image) 
Max of 1 Max of 10
 
 
 
  PREPARATION OF ARTICLES   
 
 
Please note that original articles must contain the following 
components. Please see below for further details. 
• Cover letter (must include a Conflict of Interest 
statement) 
•  Title page (excluding acknowledgements) 
•  Abstract  
•  Introduction 
• Materials (or patients) and Methods 
•  Results 
•  Discussion 
•  Acknowledgements 
•  Conflict of Interest 
• References 
•  Figure legends 
•  Tables 
•  Figures 
 
Cover Letter: The uploaded cover letter must state the 
material is original research, has not been previously 
published and has not been submitted for publication 
elsewhere while under consideration. The cover letter must 
also include a Conflict of Interest statement, which is also 
included in the text of the manuscript (see Editorial Policy 
section). 
 
Title Page: The title page should bear the title of the paper, 
the full names of all the authors, highest academic degree 
obtained, and their affiliations; also, the name, full postal 
address, telephone and fax numbers and e-mail address of 
the author to whom correspondence and offprint requests 
are to be sent (This information is also asked for on the 
electronic submission site). The title should be brief, 
informative, of 150 characters or less and should not make a 
statement or conclusion. The running title should consist of 
not more than 50 letters and spaces. It should be as brief as 
possible, convey the essential message of the paper and 
contain no abbreviations. 
 
Abstract: The Abstract should consist of one, single, 
continuous paragraph 150-250 words in length.
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Introduction: The Introduction should assume that the 
reader is knowledgeable in the field and should therefore be 
as brief as possible but can include a short historical review 
where desirable. 
 
Materials/Subjects and Methods: This section should 
contain sufficient detail, so that all experimental procedures 
can be reproduced, and include references. Methods, 
however, that have been published in detail elsewhere 
should not be described in detail. Authors should provide 
the name of the manufacturer and their location for any 
specifically named medical equipment and instruments, and 
all drugs should be identified by their pharmaceutical names, 
and by their trade name if relevant. 
 
Results and Discussion: The Results section should briefly 
present the experimental data in text, tables or figures. Tables 
and figures should not be described extensively in the text, 
either. The discussion should focus on the interpretation and 
the significance of the findings with concise objective 
comments that describe their relation to other work in the 
area. It should not repeat information in the results. The 
final paragraph should highlight the main conclusion(s), 
and provide some indication of the direction future research 
should take. 
 
Acknowledgements: These should be brief, and should 
include sources of support including sponsorship (e.g. 
university, charity, commercial organization) and sources of 
material (e.g. novel drugs) not available commercially. 
 
Conflict of Interest: Authors must declare whether or not 
there are any competing financial interests in relation to the 
work described. This information must be included at this 
stage and will be published as part of the paper. Conflict of 
interest should be noted in the cover letter and as part of the 
submission process. Please see the Conflict of Interest 
documentation in the Editorial Policy section for detailed 
information. 
 
References: Only papers directly related to the article should 
be cited. Exhaustive lists should be avoided. References 
should follow the Vancouver format. In the text, they should 
appear as numbers, and at the end of the paper they should 
be listed (double-spaced) in numerical order corresponding 
to the order of citation in the text. All authors should be 
quoted for papers with up to six authors; for papers with 
more than six authors, the first six only should be quoted, 
followed by et al. 
 
Abbreviations for titles of medical periodicals should 
conform to those used in the latest edition of Index Medicus. 
The first and last page numbers for each reference should be 
provided. Abstracts and letters must be identified as such. 
Papers in press and papers already submitted for publication 
may be included in the list of references, but no citation is 
required for work that is not yet submitted for publication. 
 
Personal communications must be allocated a number and 
included in the list of references in the usual way or simply 
referred to in the text; the authors may choose which method 
to use. In either case, authors must obtain permission from 
the individual concerned to quote his/her unpublished work. 
Journal article, up to six authors followed by et al.: 
Barbosa MDFS, Ngyen QA, Tchernev VT, Ashley JA, Detter 
JC, Blaydes SM et al. Identification of the homologous beige 
and Chediak-Higashi syndrome genes. Nature 1996; 382: 
262-65. 
 
Journal article, e-pub ahead of print: 
Yolken RH, Torrey EF. Are some cases of psychosis caused 
by microbial agents? A review of the evidence. Mol 
Psychiatry 2008; e-pub ahead of print 12 February 2008; 
doi:10.1038/mp.2008.5. 
 
Journal article, in press: 
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider 
L et al. ACNP white paper: update on use of antipsychotic 
drugs in elderly persons with dementia. 
Neuropsychopharmacology (in press). 
 
Complete book: 
Badcock C. Evolutionary Psychology: A Critical Introduction. 
Polity Press: Cambridge, UK, 2000. 
 
Chapter in book: 
Panksepp J. Affective neuroscience: a conceptual framework 
for the neurobiological study of emotions. In Strongman K 
(ed). International Reviews of Emotion Research. Wiley: 
Chichester, UK, 1991, pp 59–99. 
 
Abstract: 
Pasanen J. Epigenetics and bipolar disorder. Am J Med Genet 
C Semin Med Genet 2003; 123(Suppl 1): 45 (abstract 678). 
 
Letter to the Editor 
Kyritsis AP, Rao JS. Cloning the differences between two 
complex genomes [letter]. Science 1993; 259: 946. 
 
EndNote users should select The Pharmacogenomics 
Journal output style for the correct reference style. 
 
Tables: These should be labeled sequentially and cited 
within the text. Each table should be presented on its own 
page, numbered, and titled. Reference to table footnotes 
should be made by means of Arabic numerals. Tables 
should not duplicate the content of the text. They should 
consist of at least two columns; columns should always have 
headings. Authors should ensure that the data in the tables 
are consistent with those cited in the relevant places in the 
text, totals add up correctly, and percentages have been 
calculated correctly. Unlike figures or images, tables may be 
embedded into the word processing software if necessary, 
or supplied as separate electronic files. 
 
Figures: Figures and images should be labeled sequentially, 
numbered and cited in the text. Figure legends should be 
brief, specific, and appear on a separate manuscript page 
after the References section. Refer to (and cite) figures 
specifically in the text of the paper. Figures should not be 
embedded within the text. If a table or figure has been 
published before, the authors must obtain written 
permission to reproduce the material in both print and 
electronic formats from the copyright owner be ready to 
present it upon request. This follows for quotes, 
illustrations, and other materials taken from previously 
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published works not in the public domain. The original 
source should be cited in the figure caption or table footnote. 
The use of three-dimensional histograms is strongly 
discouraged when the addition of the third dimension gives 
no extra information. Scale markers should be used in the 
image for electron micrographs, and indicate the type of 
stain used. Detailed guidelines for submitting artwork can 
be found by downloading the guidelines PDF. 
 
House Style 
 
•  Do not make rules thinner than 1pt (0.36mm). 
• Use a coarse hatching pattern rather than shading for 
tints in graphs. 
• Color should be distinct when being used as an 
identifying tool. 
• Spaces, not commas should be used to separate 
thousands. 
• Abbreviations should be preceded by the words they 
stand for in the first instance of use. 
•  Use SI units throughout. 
•  Text should be double spaced with a wide margin. 
• At first mention of a manufacturer, the town (and state, 
if in USA) and country should be provided. 
Language Editing 
 
Authors who are not native speakers of English sometimes 
receive negative comments from referees or editors 
about the language and grammar usage in their 
manuscripts, which can contribute to a paper being 
rejected. To reduce the possibility of such problems, we 
strongly encourage such authors to take at least one of the 
following steps: 
•  Have your manuscript reviewed for clarity by a 
colleague whose native language is English. 
•  Review the tips for technical writing here: 
http://www.nature.com/authors/author
_resources/how_write.html. 
•  Use an English language editing service such as 
Nature Publishing Group Language Editing. An 
editor will improve the English to ensure that 
your meaning is clear and to identify problems 
that require your review. 
 
Please note that the use of a language editing service is at 
the author's own expense and does not guarantee that the 
article will be selected for peer review or accepted. 
 
 
 
 HOW TO SUBMIT  
 
Online Submission 
 
We only accept manuscript submissions via our online 
manuscript submission system. Before submitting a 
manuscript, authors are encouraged to consult both our 
Editorial Policies and the Submission Instructions for our 
online manuscript submission system. If you have not 
already done so, please register for an account with our 
online manuscript system. You will be able to monitor the 
status of your manuscript online throughout the editorial 
process. 
 
Submission of Revisions 
 
Authors submitting a revised manuscript after review 
are asked to include the following: 
1) A rebuttal letter, indicating point-by-point how you 
have addressed the comments raised by the 
reviewers. If you disagree with any of the points 
raised, please provide adequate justification in your 
letter. 
2)  A marked-up version of the manuscript that highlights 
changes made in response to the reviewers' comments 
in order to aid the Editors and reviewers. 
3)  A 'clean' (non-highlighted) version of the manuscript.
 
 
  POST-ACCEPTANCE  
Translational Psychiatry is an open-access journal. All papers 
are freely accessible online immediately upon publication. 
Authors are also permitted to post the final, published PDF of 
their article on a website, institutional repository or other free 
public server, immediately on publication.  
 
Articles are published under a CC BY license (Creative 
Commons Attribution 4.0 International License). The CC BY 
license is preferred by many research funding bodies. It allows 
for maximum dissemination and re-use of open access 
materials: under this license users are free to share (copy, 
distribute and transmit) and remix (adapt) the contribution 
including for commercial purposes, providing they attribute 
the contribution in the manner specified by the author or 
licensor (read the full legal code). 
 
The CC BY-NC-ND and CC BY-NC-SA licenses are available  
on request: please contact the editorial office on acceptance of 
your article to discuss these options. 
 
Under Creative Commons licenses, authors retain copyright in 
their work. 
 
Once a manuscript is accepted, the corresponding author must 
complete and sign a License to Publish form on behalf of all 
authors and return it to the editorial office. Failure to 
promptly return the form will result in delay of publication.  
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Waiver of institutional open access policies 
Please note that Harvard University FAS, MIT, Princeton, 
UCSF, University of Hawaii at Manoa, California Institute of 
Technology (Caltech) and the Georgia Institute of Technology 
have enacted Open Access policies that conflict with our own 
policy for articles published via the subscription route. If any 
corresponding or contributing authors are from these 
institutions, you will need to provide a waiver from the 
institution of every affected author, which can be obtained 
from the institution. This waiver should be submitted at the 
same time as the Open Access Licence to Publish form. This 
requirement does not apply to articles published via the open 
access route. 
 
Proofs  
The corresponding author will receive an e-mail containing a 
URL linking to the proofing site. Proof corrections must be
 returned within 48 hours of receipt. Failure to do so may 
result in delayed publication. Extensive corrections cannot be 
made at this stage.  
 
Manuscript deposition service 
 
This service is currently available to authors publishing 
original research articles. NPG’s automated manuscript 
deposition service enables authors to meet the open access 
or public access policies of all of the participating funders, 
making it simple and free for researchers to comply.
 
 
  COSTS   
 
 
Open access publication 
 
Translational Psychiatry levies the following Article-
Processing Charges (APC) (plus local taxes where 
applicable) per article accepted for publication: 
£2,400/$3,900/€2,800 for Original Articles and 
£700/$1,100/€900 for Correspondence. 
 
With regards to payment, usual credit terms are 30 days 
from receipt of invoice. Failure to pay your invoice within 
the stated credit term may result in restrictions on your 
ability to publish with Nature Publishing Group or 
Translational Psychiatry in the future, involvement of a third 
party debt collection agency, and legal proceedings.
Open access funding 
 
NPG also offers an APC support service to make it easier 
for NPG authors to discover and apply for open access 
funding. For advice on what funding is available to you and 
help in approaching funders and institutions, please contact 
us at apcwaivers@springernature.com.  
 
For more information about NPG's open access publishing 
options and policies, please see our open access homepage. 
 
 
 EDITORIAL POLICIES  
 
 
 
Translational Psychiatry is committed to maintaining high 
standards for the integrity of the published scientific record. 
Authors should take note and adhere to the journal editorial 
policies noted below. The journal will investigate any 
instances of suspected scientific fraud, image manipulation, 
plagiarism, duplicate publication, undocumented conflicts 
of interest, and other cases that compromise research ethics 
or the journal’s scientific integrity. As a member of the 
Committee on Publication Ethics, Translational Psychiatry will 
follow best practice in pursuing an investigation until the 
concern is addressed and resolved. 
 
Duplicate Publication 
 
Papers must be original and not published or submitted for 
publication elsewhere. This rule applies to non-English 
language publications. NPG allows and encourages prior 
publication on recognized community preprint servers for 
review by other scientists before formal submission to a 
journal. The details of the preprint server concerned and 
any accession numbers should be included in the cover letter 
accompanying manuscript submission. This policy does not 
extend to preprints available to the media or that are 
otherwise publicized outside the scientific community before 
or during the submission and consideration process. 
 
Permissions 
 
If a table or figure has been published before, the authors must 
obtain written permission to reproduce the material in both 
print and electronic formats from the copyright owner and be 
prepared to produce it upon request. This follows for 
quotes, illustrations and other materials taken from previously 
published works not in the public domain. The original source 
should be cited in the figure caption or table footnote. Color 
figures can be reproduced if necessary, but the authors will be 
expected to contribute towards the cost of publication. 
 
Clinical Trials 
 
As defined by the International Committee of Medical Journal 
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Editors (ICMJE), a clinical trial is any research project that 
prospectively assigns human subjects to intervention and 
comparison groups to study the cause- and-effect 
relationship between a medical intervention and a health 
outcome. A medical intervention is any intervention used to 
modify a health outcome and includes but is not limited to 
drugs, surgical procedures, devices, behavioral treatments, 
and process-of-care changes. A trial must have at least one 
prospectively assigned concurrent control or comparison 
group in order to trigger the requirement for registration. 
Nonrandomized trials are not exempt from the registration 
requirement if they meet the above criteria. 
 
When reporting experiments on human subjects, please 
indicate whether the procedures were in accordance with 
the ethical standards of the responsible committee on 
human experimentation (institutional or regional) or with 
the Helsinki Declaration of 1975 (as revised in 1983). Include 
Institutional Review Board or Animal Care and Use 
Committee approvals. 
 
All clinical trials must be registered in a public registry prior 
to submission. Translational Psychiatry follows the trials 
registration policy of the ICMJE (www.icmje.org) and 
considers only trials that have been appropriately registered 
before submission, regardless of when the trial closed to 
enrolment. Acceptable registries must meet the following 
ICMJE requirements: 
• Be publicly available, searchable, and open to all 
prospective registrants 
•  Have a validation mechanism for registration data 
•  Be managed by a not-for-profit organization 
 
Examples of registries that meet these criteria include: 
• The registry sponsored by the United States National 
Library of Medicine, www.clinicaltrials.gov 
• The International Standard Randomized Controlled 
Trial Number Registry, www.controlled-trials.com 
• The European Clinical Trials Database, 
https://eudract.ema.europa.eu 
 
Nature Publishing Group endorses the toolkits and 
guidelines produced by the following bodies: 
•  Committee on Publication Ethics  
• Good Publication Practice 
•  Medical Publishing Insights and Practices Initiative  
 
Conflict of Interest 
 
In the interests of transparency and to help readers form 
their own judgments of potential bias, authors must declare 
whether or not there are any competing financial interests in 
relation to the work described. This information must be 
included in their cover letter and on the title page of their 
manuscript. In cases where the authors declare a competing 
financial interest, a statement to that effect is published as 
part of the article. If no such conflict exists, the statement 
will simply read that the authors have nothing to disclose. 
For the purposes of this statement, competing interests are 
defined as those of a financial nature that, through their 
potential influence on behavior or content, or from 
perception of such potential influences, could undermine 
the objectivity, integrity or perceived value of a publication. 
They can include any of the following: 
• Funding: Research support (including salaries, 
equipment, supplies, reimbursement for attending 
symposia, and other expenses) by organizations that 
may gain or lose financially through this publication. 
The role of the funding body in the design of the study, 
collection and analysis of data and decision to publish 
should be stated. 
• Employment: Recent (while engaged in the research 
project), present or anticipated employment by any 
organization that may gain or lose financially through 
this publication. 
• Personal financial interests: Stocks or shares in 
companies that may gain or lose financially through 
publication; consultation fees or other forms of 
remuneration from organizations that may gain or lose 
financially; patents or patent applications whose value 
may be affected by publication. 
 
It is difficult to specify a threshold at which a financial interest 
becomes significant, but note that many US universities 
require faculty members to disclose interests exceeding 
$10,000 or 5% equity in a company. Any such figure is 
arbitrary, so we offer as one possible practical alternative 
guideline: Declare all interests that could embarrass you were 
they to become publicly known after your work was 
published. We do not consider diversified mutual funds or 
investment trusts to constitute a competing financial interest. 
 
The statement must contain an explicit and unambiguous 
statement describing any potential conflict of interest, or 
lack thereof, for any of the authors as it relates to the subject of 
the report. Examples include “Dr. Smith receives 
compensation as a consultant for XYZ Company,” “Dr. Jones 
and Dr. Smith have financial holdings in ABC Company,” or 
“Dr. Jones owns a patent on the diagnostic device described 
in this report.” These statements must be included in the 
manuscript under the heading Conflict of Interest. The 
Conflict of Interest disclosure appears in the cover letter, in 
the manuscript submission process, and before the References 
section in the manuscript. 
 
Potential conflicts of interest should be provided for all 
authors, including compensation for professional services. 
Neither the precise amount received from each entity nor 
the aggregate income from these sources needs to be 
provided. Professional services include any activities for 
which the individual is, has been, or will be compensated with 
cash, royalties, fees, stock or stock options in exchange for 
work performed, advice or counsel provided, or for other 
services related to the author’s professional knowledge and 
skills. This would include, but not necessarily be limited to, 
the identification of organizations from which the author 
received contracts or in which he or she holds an equity stake 
if professional services were provided in conjunction with the 
transaction. 
 
 
Examples of declarations are: 
•  Conflict of interest. 
 The authors declare no conflict of interest. 
•  Conflict of interest. 
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 Dr Caron's work has been funded by the NIH. He has 
received compensation as a member of the scientific 
advisory board of Acadia Pharmaceutical and owns 
stock in the company. He also has consulted for 
Lundbeck and received compensation. Dr Rothman 
and Dr Jensen declare no potential conflict of interest. 
 
Communication with the Media 
 
Material submitted must not be discussed with the media. 
We reserve the right to halt the consideration or publication 
of a paper if this condition is broken. If a paper is 
particularly newsworthy, the press release will be sent to 
our list of journalists in advance of publication with an 
embargo that forbids any coverage of the manuscript, or the 
findings of the manuscript, until the time and date clearly 
stated. Authors whose papers are scheduled for publication 
may also arrange their own publicity (for instance, through 
their institution’s press offices), but they must strictly adhere 
to our press embargo and are advised to coordinate their 
own publicity with our press office. 
 
Communication between Scientists 
 
We do not wish to hinder communication between 
scientists. We ask you to communicate with other 
researchers as much as you wish, whether on a recognized 
community preprint server, by discussion at scientific 
meetings or by online collaborative sites such as wikis, but 
we do not encourage premature publication by discussion 
with the press (beyond a formal presentation, if at a 
conference). 
 
Authorship 
 
Authorship requirements for all categories of articles largely 
conform to the “Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals,” developed by the 
International Committee of Medical Journal Editors (ICMJE), 
which state that authorship credit should be based on: 
1)  Substantial contributions to conception and design, 
acquisition of data, or analysis and interpretation of 
data; 
2)  Drafting the article or revising it critically for important 
intellectual content; and 
3)  Final approval of the version to be published. 
 
Any changes to the author list after submission, such as a 
change in the order of the authors, or the deletion or 
addition of authors, needs to be approved by a signed letter 
from every author. 
 
A manuscript will be considered for publication on the 
understanding that: 
1)  All named authors have agreed to its submission 
2)  It is not currently being considered for publication by 
another journal 
3) If the paper is accepted it will not subsequently be 
published in the same or similar form in any 
language without the consent of publishers 
 
Additional contributors to the submitted work should 
appear in the Acknowledgments. Medical writers and 
industry employees can be authors or contributors. Their 
roles, affiliations, and potential conflicts of interest should 
be included in the author list or noted in the 
Acknowledgments section concurrent with their contribution 
to the work submitted. Articles found to have been "ghost 
authored" (eg, written by unacknowledged freelance writers) 
will be considered to have violated Translational Psychiatry’s 
authorship policy. 
 
Correspondence with the Journal 
 
One author is designated the contact author for matters 
arising from the manuscript (materials requests, technical 
comments and so on). It is this author's responsibility to 
inform all co-authors of matters arising and to ensure such 
matters are dealt with promptly. After acceptance for 
publication, proofs are e-mailed to this corresponding author 
who should circulate the proof to all co-authors and 
coordinate corrections among them. 
 
Plagiarism and Fabrication 
 
Plagiarism is when an author attempts to pass off someone 
else's work as his or her own. Duplicate publication, 
sometimes called self-plagiarism, occurs when an author 
reuses substantial parts of his or her own published work 
without providing the appropriate references. If plagiarism is 
found, the journal will, as a member of the Committee on 
Publication Ethics, follow best practice in pursuing an 
investigation until the concern is addressed and resolved. 
 
Image Integrity and Standards 
 
Images submitted with a manuscript for review should be 
minimally processed (for instance, to add arrows to a 
micrograph). Authors should retain their unprocessed data 
and metadata files, as editors may request them to aid in 
manuscript evaluation. If unprocessed data is unavailable, 
manuscript evaluation may be stalled until the issue is 
resolved. 
 
A certain degree of image processing is acceptable for 
publication, but the final image must correctly represent the 
original data and conform to community standards. The 
guidelines below will aid in accurate data presentation at 
the image processing level: 
• Authors should list all image acquisition tools and 
image processing software packages used. Authors 
should document key image-gathering settings and 
processing manipulations in the Methods section. 
• Images gathered at different times or from different 
locations should not be combined into a single image, 
unless it is stated that the resultant image is a product of 
time-averaged data or a time-lapse sequence. If 
juxtaposing images is essential, the borders should be 
clearly demarcated in the figure and described in the 
legend. 
• Touch-up tools, such as cloning and healing tools in 
Photoshop, or any feature that deliberately obscures 
manipulations, is to be avoided. 
•  Processing (such as changing brightness and contrast) 
is appropriate only when it is applied equally across 
the entire image and is applied equally to controls. 
Contrast should not be adjusted so that data disappear. 
Excessive manipulations, such as processing to 
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emphasize one region in the image at the expense of 
others (for example, through the use of a biased choice 
of threshold settings), is inappropriate, as is 
emphasizing experimental data relative to the control. 
 
For gels and blots, positive and negative controls, as well as 
molecular size markers, should be included on each gel and 
blot – either in the main figure or an expanded data 
supplementary figure. The display of cropped gels and blots 
in the main paper is encouraged if it improves the clarity 
and conciseness of the presentation. In such cases, the 
cropping must be mentioned in the figure legend. 
• Vertically sliced gels that juxtapose lanes that were not 
contiguous in the experiment must have a clear 
separation or a black line delineating the boundary 
between the gels. 
• Cropped gels in the paper must retain important 
bands. 
• Cropped blots in the body of the paper should retain 
at least six band widths above and below the band. 
• High-contrast gels and blots are discouraged, as 
overexposure may mask additional bands. Authors 
should strive for exposures with gray backgrounds. 
Immunoblots should be surrounded by a black line to 
indicate the borders of the blot, if the background is 
faint. 
• For quantitative comparisons, appropriate reagents, 
controls and imaging methods with linear signal 
ranges should be used. 
 
Microscopy adjustments should be applied to the entire 
image. Threshold manipulation, expansion or contraction of 
signal ranges and the altering of high signals should be 
avoided. If ‘pseudo-coloring’ and nonlinear adjustment (for 
example ‘gamma changes’) are used, this must be disclosed. 
Adjustments of individual color channels are sometimes 
necessary on ‘merged’ images, but this should be noted in 
the figure legend. We encourage inclusion of the following 
with the final revised version of the manuscript for 
publication: 
•  In the Methods section, specify the type of equipment 
(microscopes/objective lenses, cameras, detectors, filter 
model and batch number) and acquisition software 
used. Although we appreciate that there is some 
variation between instruments, equipment settings for 
critical measurements should also be listed. 
• The display lookup table (LUT) and the quantitative 
map between the LUT and the bitmap should be 
provided, especially when rainbow pseudo-colour is 
used. It should be stated if the LUT is linear and covers 
the full range of the data. 
• Processing  software  should  be  named  and 
manipulations indicated (such as type of deconvolution, 
three-dimensional reconstructions, surface and volume 
rendering, 'gamma changes', filtering, thresholding and 
projection). 
• Authors should state the measured resolution at which 
an image was acquired and any downstream 
processing or averaging that enhances the resolution of 
the image. 
 
Availability of Data and Materials 
 
As of March 2014, Translational Psychiatry requires authors of 
papers that are sent for external review to include in their 
manuscripts relevant details about several elements of 
experimental and analytical design. This initiative aims to 
improve the transparency of reporting and the reproducibility 
of published results, focusing on elements of methodological 
information that are frequently poorly reported. Authors 
being asked to resubmit a manuscript will be asked to confirm 
that these elements are included by filling out a checklist that 
will be made available to the editor and reviewers. 
An inherent principle of publication is that others should be 
able to replicate and build upon the authors’ published claims. 
Therefore, a condition of publication is that authors are 
required to make materials, data, and associated protocols 
available in a publicly accessible database. Where one does 
not exist, the information must be made available to referees 
at submission and to readers promptly upon request. Any 
restrictions on material availability or other relevant 
information must be disclosed in the manuscript’s Methods 
section and should include details of how materials and 
information may be obtained. 
 
Sequences, Structures and “Omics” 
 
Papers reporting protein or DNA sequences and molecular 
structures will not be accepted without an accession number to 
Genbank/EMBL/DDBJ, Protein DataBank, SWISS-PROT or 
other publicly available database in general use in the field 
that gives free access to researchers from the date of 
publication. 
 
Authors of papers describing structures of biological 
macromolecules must provide experimental data upon the 
request of Editor if they are not already freely accessible in a 
publicly  available  database  such  as  Protein DataBank, 
Nucleic Acids Database or Biological Magnetic Resonance 
Databank. 
 
Gene Nomenclature 
 
Authors should use approved nomenclature for gene symbols, 
and use symbols rather than italicized full names (Ttn, not 
titin). Please consult the appropriate nomenclature databases 
for correct gene names and symbols. Approved human gene 
symbols are provided by HUGO Gene Nomenclature 
Committee (HGNC), www.genenames.org. Approved mouse 
symbols are provided by The Jackson Laboratory,  
www.informatics.jax.org/mgihome/nomen. For proposed 
gene names that are not already approved, please submit the 
gene symbols to the appropriate nomenclature committees as 
soon as possible, as these must be deposited and approved 
before publication of an article. Avoid listing multiple names 
of genes (or proteins) separated by a slash, as in 
'Oct4/Pou5f1', as this is ambiguous (it could mean a ratio, a 
complex, alternative names or different subunits). Use one 
name throughout and include the other at first mention: 'Oct4 
(also known as Pou5f1)'. 
 
Human and Other Animal Experiments 
 
For primary research manuscripts reporting experiments on 
live vertebrates and/or higher invertebrates, the 
corresponding author must confirm that all experiments 
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were performed in accordance with relevant guidelines and 
regulations. The manuscript must include a statement  
identifying the institutional and/or licensing committee 
approving the experiments, including any relevant details 
regarding animal welfare, patient anonymity, drug side 
effects and informed consent. 
 
For experiments involving human subjects, authors must 
identify the committee approving the experiments, and 
include with their submission a statement confirming that 
informed consent was obtained from all subjects. 
 
Biosecurity Policy 
 
The Editor may seek advice about submitted papers not 
only from technical reviewers but also on any aspect of a 
paper that raises concerns. These may include, for example, 
ethical issues or issues of data or materials access. 
Occasionally, concerns may also relate to the implications to 
society of publishing a paper, including threats to security. 
In such circumstances, advice will usually be sought 
simultaneously with the technical peer-review process. As 
in all publishing decisions, the ultimate decision whether to 
publish is the responsibility of the editor of the journal 
concerned. 
 
Peer Review 
 
All contributions that are selected for peer review are sent to 
two or more independent reviewers. The identity of 
reviewers is confidential and manuscripts are considered 
private information. Papers may be rejected without external 
review at the Editor’s discretion. Authors are encouraged to 
suggest or recommend for exclusion reviewers at the time of 
submissions. 
 
Anonymity and Confidentiality 
 
Reviewers' identities are not released to authors, except 
when reviewers specifically ask to be identified. If this is the 
case, and reviewers wish to reveal their identities while the 
manuscript is under consideration, this needs to be done 
through the Editor; however, it is the journal’s strong 
preference this process remains anonymous both during  
and after the manuscript’s consideration. Should a reviewer 
contact an author directly, we ask authors to inform the 
Editor as soon as possible. We prohibit any attempt by 
authors to confront reviewers or determine their identities. 
Our own policy is to neither confirm nor deny any 
speculation about reviewers' identities, and we encourage 
reviewers to adopt a similar policy. 
 
 
 
Selecting Peer Reviewers 
 
Reviewer selection is critical to the publication process, and 
we base our choices on many factors, including expertise, 
reputation, and specific recommendations. 
 
Correction and Retraction Process 
 
We recognize our responsibility to correct errors. Content 
published online is final and cannot be amended. Please 
note the following policy for making corrections to peer- 
reviewed content: 
•  Erratum. Notification of an important error made by the 
journal that affects the publication record or the 
scientific integrity of the paper, or the reputation of 
the authors, or of the journal. 
•  Corrigendum. Notification of an important error made 
by the author that affects the publication record or the 
scientific integrity of the paper, or the reputation of 
the authors or the journal. 
• Retraction. Notification of invalid results. All co- authors 
must sign a retraction specifying the error and stating 
briefly how the conclusions are affected. 
 
Decisions about corrections are made by the Editor 
(sometimes with peer-reviewers' advice) and this sometimes 
involves author consultation. Requests to make corrections 
that do not affect the paper in a significant way or impair 
the reader's understanding of the contribution (a spelling 
mistake or grammatical error, for example) are not 
considered. 
 
In cases where co-authors disagree about a correction, the 
editors will take advice from independent peer-reviewers. 
 
 
 FURTHER INFORMATION   
 
For inquiries related to submission requirements or submitted manuscripts, please contact the editorial office. For inquiries 
related to advertising, subscriptions, permissions, papers in production or publishing a supplement, please contact the  
publisher’s office . 
